nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—HTR1D—meninx—malignant glioma	0.0911	0.196	CbGeAlD
Dihydroergotamine—HTR1B—dura mater—malignant glioma	0.0866	0.187	CbGeAlD
Dihydroergotamine—HTR1D—dura mater—malignant glioma	0.0838	0.181	CbGeAlD
Dihydroergotamine—CYP3A4—Temozolomide—malignant glioma	0.0756	1	CbGbCtD
Dihydroergotamine—HTR1B—telencephalic ventricle—malignant glioma	0.0216	0.0465	CbGeAlD
Dihydroergotamine—HTR1D—telencephalic ventricle—malignant glioma	0.0209	0.045	CbGeAlD
Dihydroergotamine—Vasospasm—Carmustine—malignant glioma	0.0179	0.0461	CcSEcCtD
Dihydroergotamine—HTR1A—telencephalic ventricle—malignant glioma	0.0174	0.0375	CbGeAlD
Dihydroergotamine—HTR1B—blood vessel—malignant glioma	0.0107	0.023	CbGeAlD
Dihydroergotamine—HTR1D—blood vessel—malignant glioma	0.0103	0.0223	CbGeAlD
Dihydroergotamine—Cerebration impaired—Temozolomide—malignant glioma	0.01	0.0259	CcSEcCtD
Dihydroergotamine—Parosmia—Temozolomide—malignant glioma	0.00909	0.0235	CcSEcCtD
Dihydroergotamine—HTR6—telencephalon—malignant glioma	0.00859	0.0185	CbGeAlD
Dihydroergotamine—Influenza-like symptoms—Temozolomide—malignant glioma	0.00825	0.0213	CcSEcCtD
Dihydroergotamine—Stupor—Carmustine—malignant glioma	0.00817	0.0211	CcSEcCtD
Dihydroergotamine—Rigors—Temozolomide—malignant glioma	0.00722	0.0186	CcSEcCtD
Dihydroergotamine—Petechiae—Temozolomide—malignant glioma	0.00717	0.0185	CcSEcCtD
Dihydroergotamine—Speech disorder—Carmustine—malignant glioma	0.00709	0.0183	CcSEcCtD
Dihydroergotamine—Speech disorder—Temozolomide—malignant glioma	0.00686	0.0177	CcSEcCtD
Dihydroergotamine—Disturbance in attention—Temozolomide—malignant glioma	0.00681	0.0176	CcSEcCtD
Dihydroergotamine—Herpes simplex—Temozolomide—malignant glioma	0.0064	0.0165	CcSEcCtD
Dihydroergotamine—Gait disturbance—Carmustine—malignant glioma	0.00625	0.0161	CcSEcCtD
Dihydroergotamine—Gait disturbance—Temozolomide—malignant glioma	0.00604	0.0156	CcSEcCtD
Dihydroergotamine—Vaginal inflammation—Temozolomide—malignant glioma	0.0059	0.0152	CcSEcCtD
Dihydroergotamine—Depressed level of consciousness—Carmustine—malignant glioma	0.00589	0.0152	CcSEcCtD
Dihydroergotamine—HTR1B—brainstem—malignant glioma	0.00584	0.0126	CbGeAlD
Dihydroergotamine—Influenza like illness—Temozolomide—malignant glioma	0.00573	0.0148	CcSEcCtD
Dihydroergotamine—Depressed level of consciousness—Temozolomide—malignant glioma	0.00569	0.0147	CcSEcCtD
Dihydroergotamine—HTR1D—brainstem—malignant glioma	0.00565	0.0122	CbGeAlD
Dihydroergotamine—Vaginal infection—Temozolomide—malignant glioma	0.00557	0.0144	CcSEcCtD
Dihydroergotamine—Abnormal vision—Carmustine—malignant glioma	0.00532	0.0137	CcSEcCtD
Dihydroergotamine—Mental disability—Carmustine—malignant glioma	0.00529	0.0137	CcSEcCtD
Dihydroergotamine—HTR1B—telencephalon—malignant glioma	0.00518	0.0112	CbGeAlD
Dihydroergotamine—Abnormal vision—Temozolomide—malignant glioma	0.00514	0.0133	CcSEcCtD
Dihydroergotamine—Mental disability—Temozolomide—malignant glioma	0.00512	0.0132	CcSEcCtD
Dihydroergotamine—Swelling—Carmustine—malignant glioma	0.00502	0.013	CcSEcCtD
Dihydroergotamine—Ear pain—Temozolomide—malignant glioma	0.00502	0.0129	CcSEcCtD
Dihydroergotamine—HTR1D—telencephalon—malignant glioma	0.00501	0.0108	CbGeAlD
Dihydroergotamine—Eye pain—Carmustine—malignant glioma	0.00491	0.0127	CcSEcCtD
Dihydroergotamine—HTR6—central nervous system—malignant glioma	0.00488	0.0105	CbGeAlD
Dihydroergotamine—Injury—Carmustine—malignant glioma	0.00482	0.0124	CcSEcCtD
Dihydroergotamine—Eye pain—Temozolomide—malignant glioma	0.00474	0.0122	CcSEcCtD
Dihydroergotamine—HTR1A—brainstem—malignant glioma	0.00471	0.0102	CbGeAlD
Dihydroergotamine—HTR2B—telencephalon—malignant glioma	0.00466	0.0101	CbGeAlD
Dihydroergotamine—Hot flush—Temozolomide—malignant glioma	0.00458	0.0118	CcSEcCtD
Dihydroergotamine—Menopausal symptoms—Temozolomide—malignant glioma	0.00454	0.0117	CcSEcCtD
Dihydroergotamine—Face oedema—Carmustine—malignant glioma	0.00428	0.011	CcSEcCtD
Dihydroergotamine—HTR1A—telencephalon—malignant glioma	0.00418	0.00901	CbGeAlD
Dihydroergotamine—Face oedema—Temozolomide—malignant glioma	0.00413	0.0107	CcSEcCtD
Dihydroergotamine—Muscular weakness—Carmustine—malignant glioma	0.00391	0.0101	CcSEcCtD
Dihydroergotamine—HTR6—brain—malignant glioma	0.00388	0.00836	CbGeAlD
Dihydroergotamine—Dysphagia—Carmustine—malignant glioma	0.00383	0.00988	CcSEcCtD
Dihydroergotamine—Muscular weakness—Temozolomide—malignant glioma	0.00377	0.00974	CcSEcCtD
Dihydroergotamine—HTR1B—midbrain—malignant glioma	0.00372	0.00802	CbGeAlD
Dihydroergotamine—Dysphagia—Temozolomide—malignant glioma	0.0037	0.00955	CcSEcCtD
Dihydroergotamine—HTR1B—spinal cord—malignant glioma	0.00363	0.00782	CbGeAlD
Dihydroergotamine—Sweating increased—Temozolomide—malignant glioma	0.0036	0.0093	CcSEcCtD
Dihydroergotamine—HTR1D—midbrain—malignant glioma	0.0036	0.00776	CbGeAlD
Dihydroergotamine—Bronchitis—Temozolomide—malignant glioma	0.00356	0.00918	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Temozolomide—malignant glioma	0.00344	0.00887	CcSEcCtD
Dihydroergotamine—Pollakiuria—Temozolomide—malignant glioma	0.00342	0.00882	CcSEcCtD
Dihydroergotamine—ABCB1—blood vessel—malignant glioma	0.00336	0.00725	CbGeAlD
Dihydroergotamine—Sinusitis—Temozolomide—malignant glioma	0.00309	0.00799	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Carmustine—malignant glioma	0.00305	0.00787	CcSEcCtD
Dihydroergotamine—HTR1A—midbrain—malignant glioma	0.003	0.00647	CbGeAlD
Dihydroergotamine—Visual impairment—Carmustine—malignant glioma	0.00295	0.00762	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Temozolomide—malignant glioma	0.00295	0.0076	CcSEcCtD
Dihydroergotamine—HTR1B—central nervous system—malignant glioma	0.00294	0.00635	CbGeAlD
Dihydroergotamine—Pharyngitis—Temozolomide—malignant glioma	0.00294	0.00759	CcSEcCtD
Dihydroergotamine—ADRA2A—telencephalon—malignant glioma	0.00293	0.00632	CbGeAlD
Dihydroergotamine—HTR1A—spinal cord—malignant glioma	0.00293	0.00631	CbGeAlD
Dihydroergotamine—Visual impairment—Temozolomide—malignant glioma	0.00285	0.00737	CcSEcCtD
Dihydroergotamine—HTR1D—central nervous system—malignant glioma	0.00285	0.00614	CbGeAlD
Dihydroergotamine—Flushing—Carmustine—malignant glioma	0.00284	0.00734	CcSEcCtD
Dihydroergotamine—Tinnitus—Temozolomide—malignant glioma	0.00276	0.00713	CcSEcCtD
Dihydroergotamine—Flushing—Temozolomide—malignant glioma	0.00275	0.00709	CcSEcCtD
Dihydroergotamine—Chills—Temozolomide—malignant glioma	0.00266	0.00686	CcSEcCtD
Dihydroergotamine—HTR2B—central nervous system—malignant glioma	0.00265	0.00572	CbGeAlD
Dihydroergotamine—Tremor—Carmustine—malignant glioma	0.0025	0.00645	CcSEcCtD
Dihydroergotamine—Agitation—Carmustine—malignant glioma	0.00245	0.00633	CcSEcCtD
Dihydroergotamine—Tremor—Temozolomide—malignant glioma	0.00241	0.00623	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Temozolomide—malignant glioma	0.00239	0.00617	CcSEcCtD
Dihydroergotamine—HTR1A—central nervous system—malignant glioma	0.00238	0.00512	CbGeAlD
Dihydroergotamine—Agitation—Temozolomide—malignant glioma	0.00237	0.00611	CcSEcCtD
Dihydroergotamine—HTR1B—brain—malignant glioma	0.00234	0.00504	CbGeAlD
Dihydroergotamine—Malaise—Temozolomide—malignant glioma	0.00232	0.006	CcSEcCtD
Dihydroergotamine—HTR1A—cerebellum—malignant glioma	0.00232	0.00501	CbGeAlD
Dihydroergotamine—Vertigo—Temozolomide—malignant glioma	0.00232	0.00598	CcSEcCtD
Dihydroergotamine—Hypertension—Carmustine—malignant glioma	0.0023	0.00594	CcSEcCtD
Dihydroergotamine—ADRA2A—medulla oblongata—malignant glioma	0.0023	0.00496	CbGeAlD
Dihydroergotamine—Palpitations—Temozolomide—malignant glioma	0.00228	0.00588	CcSEcCtD
Dihydroergotamine—Myalgia—Carmustine—malignant glioma	0.00227	0.00586	CcSEcCtD
Dihydroergotamine—Anxiety—Carmustine—malignant glioma	0.00226	0.00584	CcSEcCtD
Dihydroergotamine—HTR1D—brain—malignant glioma	0.00226	0.00488	CbGeAlD
Dihydroergotamine—Hypertension—Temozolomide—malignant glioma	0.00223	0.00574	CcSEcCtD
Dihydroergotamine—Confusional state—Carmustine—malignant glioma	0.00219	0.00567	CcSEcCtD
Dihydroergotamine—Arthralgia—Temozolomide—malignant glioma	0.00219	0.00566	CcSEcCtD
Dihydroergotamine—Myalgia—Temozolomide—malignant glioma	0.00219	0.00566	CcSEcCtD
Dihydroergotamine—Anxiety—Temozolomide—malignant glioma	0.00219	0.00564	CcSEcCtD
Dihydroergotamine—Oedema—Carmustine—malignant glioma	0.00218	0.00562	CcSEcCtD
Dihydroergotamine—Discomfort—Temozolomide—malignant glioma	0.00217	0.0056	CcSEcCtD
Dihydroergotamine—Dry mouth—Temozolomide—malignant glioma	0.00215	0.00554	CcSEcCtD
Dihydroergotamine—Tachycardia—Carmustine—malignant glioma	0.00212	0.00548	CcSEcCtD
Dihydroergotamine—Confusional state—Temozolomide—malignant glioma	0.00212	0.00548	CcSEcCtD
Dihydroergotamine—HTR2B—brain—malignant glioma	0.0021	0.00454	CbGeAlD
Dihydroergotamine—ADRA2A—midbrain—malignant glioma	0.0021	0.00454	CbGeAlD
Dihydroergotamine—Oedema—Temozolomide—malignant glioma	0.0021	0.00543	CcSEcCtD
Dihydroergotamine—Anorexia—Carmustine—malignant glioma	0.00208	0.00536	CcSEcCtD
Dihydroergotamine—ADRA2A—spinal cord—malignant glioma	0.00205	0.00442	CbGeAlD
Dihydroergotamine—Hypotension—Carmustine—malignant glioma	0.00203	0.00525	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Temozolomide—malignant glioma	0.00203	0.00525	CcSEcCtD
Dihydroergotamine—ABCB1—embryo—malignant glioma	0.00201	0.00433	CbGeAlD
Dihydroergotamine—Anorexia—Temozolomide—malignant glioma	0.00201	0.00518	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Carmustine—malignant glioma	0.00198	0.00512	CcSEcCtD
Dihydroergotamine—Insomnia—Carmustine—malignant glioma	0.00197	0.00508	CcSEcCtD
Dihydroergotamine—Paraesthesia—Carmustine—malignant glioma	0.00195	0.00505	CcSEcCtD
Dihydroergotamine—Dyspnoea—Carmustine—malignant glioma	0.00194	0.00501	CcSEcCtD
Dihydroergotamine—Somnolence—Carmustine—malignant glioma	0.00194	0.005	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.00192	0.00495	CcSEcCtD
Dihydroergotamine—Insomnia—Temozolomide—malignant glioma	0.0019	0.00491	CcSEcCtD
Dihydroergotamine—Decreased appetite—Carmustine—malignant glioma	0.00189	0.00488	CcSEcCtD
Dihydroergotamine—Paraesthesia—Temozolomide—malignant glioma	0.00189	0.00488	CcSEcCtD
Dihydroergotamine—HTR1A—brain—malignant glioma	0.00189	0.00407	CbGeAlD
Dihydroergotamine—Dyspnoea—Temozolomide—malignant glioma	0.00188	0.00484	CcSEcCtD
Dihydroergotamine—Somnolence—Temozolomide—malignant glioma	0.00187	0.00483	CcSEcCtD
Dihydroergotamine—Pain—Carmustine—malignant glioma	0.00186	0.0048	CcSEcCtD
Dihydroergotamine—Dyspepsia—Temozolomide—malignant glioma	0.00185	0.00478	CcSEcCtD
Dihydroergotamine—Decreased appetite—Temozolomide—malignant glioma	0.00183	0.00472	CcSEcCtD
Dihydroergotamine—Fatigue—Temozolomide—malignant glioma	0.00181	0.00468	CcSEcCtD
Dihydroergotamine—Pain—Temozolomide—malignant glioma	0.0018	0.00464	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Carmustine—malignant glioma	0.00179	0.00463	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Carmustine—malignant glioma	0.00178	0.00459	CcSEcCtD
Dihydroergotamine—ABCB1—retina—malignant glioma	0.00177	0.00383	CbGeAlD
Dihydroergotamine—Feeling abnormal—Temozolomide—malignant glioma	0.00173	0.00447	CcSEcCtD
Dihydroergotamine—Body temperature increased—Carmustine—malignant glioma	0.00172	0.00444	CcSEcCtD
Dihydroergotamine—Abdominal pain—Carmustine—malignant glioma	0.00172	0.00444	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Temozolomide—malignant glioma	0.00172	0.00444	CcSEcCtD
Dihydroergotamine—Urticaria—Temozolomide—malignant glioma	0.00167	0.00431	CcSEcCtD
Dihydroergotamine—ADRA2A—central nervous system—malignant glioma	0.00167	0.00359	CbGeAlD
Dihydroergotamine—Abdominal pain—Temozolomide—malignant glioma	0.00166	0.00429	CcSEcCtD
Dihydroergotamine—Body temperature increased—Temozolomide—malignant glioma	0.00166	0.00429	CcSEcCtD
Dihydroergotamine—ABCB1—telencephalon—malignant glioma	0.00163	0.00352	CbGeAlD
Dihydroergotamine—ADRA2A—cerebellum—malignant glioma	0.00163	0.00351	CbGeAlD
Dihydroergotamine—Hypersensitivity—Carmustine—malignant glioma	0.0016	0.00414	CcSEcCtD
Dihydroergotamine—Asthenia—Carmustine—malignant glioma	0.00156	0.00403	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Temozolomide—malignant glioma	0.00155	0.004	CcSEcCtD
Dihydroergotamine—Asthenia—Temozolomide—malignant glioma	0.00151	0.0039	CcSEcCtD
Dihydroergotamine—Diarrhoea—Carmustine—malignant glioma	0.00149	0.00384	CcSEcCtD
Dihydroergotamine—Pruritus—Temozolomide—malignant glioma	0.00149	0.00384	CcSEcCtD
Dihydroergotamine—Dizziness—Carmustine—malignant glioma	0.00144	0.00372	CcSEcCtD
Dihydroergotamine—Diarrhoea—Temozolomide—malignant glioma	0.00144	0.00372	CcSEcCtD
Dihydroergotamine—Dizziness—Temozolomide—malignant glioma	0.00139	0.00359	CcSEcCtD
Dihydroergotamine—Vomiting—Carmustine—malignant glioma	0.00138	0.00357	CcSEcCtD
Dihydroergotamine—Rash—Carmustine—malignant glioma	0.00137	0.00354	CcSEcCtD
Dihydroergotamine—Dermatitis—Carmustine—malignant glioma	0.00137	0.00354	CcSEcCtD
Dihydroergotamine—Headache—Carmustine—malignant glioma	0.00136	0.00352	CcSEcCtD
Dihydroergotamine—Vomiting—Temozolomide—malignant glioma	0.00134	0.00345	CcSEcCtD
Dihydroergotamine—Rash—Temozolomide—malignant glioma	0.00133	0.00342	CcSEcCtD
Dihydroergotamine—Dermatitis—Temozolomide—malignant glioma	0.00133	0.00342	CcSEcCtD
Dihydroergotamine—ADRA2A—brain—malignant glioma	0.00132	0.00285	CbGeAlD
Dihydroergotamine—Headache—Temozolomide—malignant glioma	0.00132	0.0034	CcSEcCtD
Dihydroergotamine—CYP3A4—central nervous system—malignant glioma	0.00131	0.00283	CbGeAlD
Dihydroergotamine—Nausea—Carmustine—malignant glioma	0.00129	0.00334	CcSEcCtD
Dihydroergotamine—ABCB1—medulla oblongata—malignant glioma	0.00128	0.00276	CbGeAlD
Dihydroergotamine—Nausea—Temozolomide—malignant glioma	0.00125	0.00323	CcSEcCtD
Dihydroergotamine—ABCB1—midbrain—malignant glioma	0.00117	0.00253	CbGeAlD
Dihydroergotamine—ABCB1—spinal cord—malignant glioma	0.00114	0.00247	CbGeAlD
Dihydroergotamine—ABCB1—central nervous system—malignant glioma	0.000928	0.002	CbGeAlD
Dihydroergotamine—ABCB1—cerebellum—malignant glioma	0.000907	0.00195	CbGeAlD
Dihydroergotamine—ABCB1—brain—malignant glioma	0.000737	0.00159	CbGeAlD
Dihydroergotamine—ADRA2A—Signaling Pathways—NTRK1—malignant glioma	2.3e-05	0.000315	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP2B6—malignant glioma	2.29e-05	0.000314	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—AKT2—malignant glioma	2.28e-05	0.000312	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—BCHE—malignant glioma	2.27e-05	0.000311	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—EGFR—malignant glioma	2.27e-05	0.000311	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—IL2—malignant glioma	2.26e-05	0.00031	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PIK3CD—malignant glioma	2.26e-05	0.000309	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TERT—malignant glioma	2.25e-05	0.000308	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—SLC5A5—malignant glioma	2.25e-05	0.000307	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—KRAS—malignant glioma	2.24e-05	0.000306	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PIK3CD—malignant glioma	2.24e-05	0.000306	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—PIK3CA—malignant glioma	2.23e-05	0.000306	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—PIK3CD—malignant glioma	2.22e-05	0.000304	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—PIK3CA—malignant glioma	2.22e-05	0.000303	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—KRAS—malignant glioma	2.21e-05	0.000302	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—BRAF—malignant glioma	2.2e-05	0.000301	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PDGFB—malignant glioma	2.2e-05	0.000301	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PIK3CD—malignant glioma	2.19e-05	0.0003	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—KRAS—malignant glioma	2.19e-05	0.0003	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—FGFR1—malignant glioma	2.19e-05	0.000299	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—PIK3CA—malignant glioma	2.17e-05	0.000297	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—FGF2—malignant glioma	2.16e-05	0.000295	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—HIF1A—malignant glioma	2.16e-05	0.000295	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—KRAS—malignant glioma	2.15e-05	0.000294	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—FGF2—malignant glioma	2.14e-05	0.000293	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—AKT2—malignant glioma	2.14e-05	0.000293	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MMP3—malignant glioma	2.14e-05	0.000293	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—EGFR—malignant glioma	2.13e-05	0.000292	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—PIK3CB—malignant glioma	2.13e-05	0.000292	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CDKN2B—malignant glioma	2.12e-05	0.00029	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—FGF2—malignant glioma	2.1e-05	0.000287	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—IDH1—malignant glioma	2.1e-05	0.000287	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CAV1—malignant glioma	2.08e-05	0.000285	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—RAF1—malignant glioma	2.07e-05	0.000283	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—KDR—malignant glioma	2.06e-05	0.000282	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PIK3CD—malignant glioma	2.06e-05	0.000282	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PTK2—malignant glioma	2.06e-05	0.000282	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—PIK3CA—malignant glioma	2.06e-05	0.000281	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—CXCL8—malignant glioma	2.05e-05	0.00028	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—PIK3CA—malignant glioma	2.04e-05	0.000279	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SPHK1—malignant glioma	2.03e-05	0.000278	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—PIK3CA—malignant glioma	2.03e-05	0.000278	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HES1—malignant glioma	2.02e-05	0.000277	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MDM2—malignant glioma	2.02e-05	0.000276	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—KRAS—malignant glioma	2.02e-05	0.000276	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—RAF1—malignant glioma	2.01e-05	0.000276	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—PIK3CA—malignant glioma	2.01e-05	0.000275	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NCOR1—malignant glioma	2.01e-05	0.000275	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MDM2—malignant glioma	2.01e-05	0.000274	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—RAF1—malignant glioma	2e-05	0.000273	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—ERBB2—malignant glioma	1.99e-05	0.000273	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—TP53—malignant glioma	1.99e-05	0.000272	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP2C18—malignant glioma	1.99e-05	0.000272	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—F2—malignant glioma	1.98e-05	0.000272	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—FN1—malignant glioma	1.98e-05	0.000272	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—RAF1—malignant glioma	1.98e-05	0.000271	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—ERBB2—malignant glioma	1.98e-05	0.000271	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—PIK3CA—malignant glioma	1.97e-05	0.00027	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—FGF2—malignant glioma	1.97e-05	0.00027	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PIK3CB—malignant glioma	1.97e-05	0.000269	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MDM2—malignant glioma	1.96e-05	0.000269	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—BAD—malignant glioma	1.96e-05	0.000268	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CAV1—malignant glioma	1.96e-05	0.000268	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—IL2—malignant glioma	1.96e-05	0.000268	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—RAF1—malignant glioma	1.96e-05	0.000268	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PIK3CB—malignant glioma	1.95e-05	0.000267	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NOTCH1—malignant glioma	1.94e-05	0.000266	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—PIK3CB—malignant glioma	1.94e-05	0.000265	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—ERBB2—malignant glioma	1.94e-05	0.000265	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PDGFRA—malignant glioma	1.93e-05	0.000263	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PIK3CB—malignant glioma	1.91e-05	0.000261	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CD80—malignant glioma	1.9e-05	0.00026	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—APC—malignant glioma	1.9e-05	0.00026	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CG—malignant glioma	1.9e-05	0.00026	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CXCL8—malignant glioma	1.89e-05	0.000258	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—EGF—malignant glioma	1.88e-05	0.000257	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CXCL8—malignant glioma	1.87e-05	0.000257	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SPP1—malignant glioma	1.87e-05	0.000256	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PTPN11—malignant glioma	1.87e-05	0.000255	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CXCL8—malignant glioma	1.86e-05	0.000255	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—PIK3CA—malignant glioma	1.85e-05	0.000253	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MDM2—malignant glioma	1.84e-05	0.000252	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—RAF1—malignant glioma	1.84e-05	0.000251	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CXCL8—malignant glioma	1.84e-05	0.000251	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—AKT1—malignant glioma	1.83e-05	0.00025	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—ERBB2—malignant glioma	1.82e-05	0.000249	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—AKT1—malignant glioma	1.81e-05	0.000248	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GSTP1—malignant glioma	1.81e-05	0.000248	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CASP3—malignant glioma	1.81e-05	0.000247	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IL2—malignant glioma	1.81e-05	0.000247	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PIK3CB—malignant glioma	1.79e-05	0.000246	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CASP3—malignant glioma	1.79e-05	0.000246	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL2—malignant glioma	1.79e-05	0.000245	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—BRAF—malignant glioma	1.79e-05	0.000244	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CG—malignant glioma	1.79e-05	0.000244	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL2—malignant glioma	1.78e-05	0.000243	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—AKT1—malignant glioma	1.77e-05	0.000243	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TERT—malignant glioma	1.77e-05	0.000242	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CAT—malignant glioma	1.76e-05	0.000241	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CASP3—malignant glioma	1.76e-05	0.00024	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL2—malignant glioma	1.75e-05	0.00024	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—AKT2—malignant glioma	1.74e-05	0.000238	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—EGFR—malignant glioma	1.73e-05	0.000237	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PDGFB—malignant glioma	1.73e-05	0.000237	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CXCL8—malignant glioma	1.72e-05	0.000236	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PPARG—malignant glioma	1.72e-05	0.000236	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—FGFR1—malignant glioma	1.72e-05	0.000235	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MMP9—malignant glioma	1.71e-05	0.000234	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PTEN—malignant glioma	1.7e-05	0.000232	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MMP9—malignant glioma	1.7e-05	0.000232	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HIF1A—malignant glioma	1.69e-05	0.000232	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PTEN—malignant glioma	1.69e-05	0.000231	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—AKT1—malignant glioma	1.68e-05	0.00023	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CD—malignant glioma	1.67e-05	0.000228	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—AKT1—malignant glioma	1.67e-05	0.000228	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—NCOR1—malignant glioma	1.66e-05	0.000227	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MMP9—malignant glioma	1.66e-05	0.000227	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—AKT1—malignant glioma	1.66e-05	0.000227	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—PIK3CA—malignant glioma	1.65e-05	0.000226	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PTEN—malignant glioma	1.65e-05	0.000226	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CASP3—malignant glioma	1.65e-05	0.000226	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL2—malignant glioma	1.65e-05	0.000225	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—AKT1—malignant glioma	1.64e-05	0.000225	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CAV1—malignant glioma	1.64e-05	0.000224	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—KRAS—malignant glioma	1.63e-05	0.000224	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—KDR—malignant glioma	1.62e-05	0.000222	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—AKT1—malignant glioma	1.61e-05	0.00022	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTT1—malignant glioma	1.61e-05	0.00022	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—FGF2—malignant glioma	1.6e-05	0.000219	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CD—malignant glioma	1.57e-05	0.000215	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MMP9—malignant glioma	1.56e-05	0.000213	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—F2—malignant glioma	1.56e-05	0.000213	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—FN1—malignant glioma	1.56e-05	0.000213	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PTEN—malignant glioma	1.55e-05	0.000212	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—BAD—malignant glioma	1.54e-05	0.000211	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—VEGFA—malignant glioma	1.53e-05	0.00021	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NOTCH1—malignant glioma	1.53e-05	0.000209	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—VEGFA—malignant glioma	1.52e-05	0.000208	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—STAT3—malignant glioma	1.52e-05	0.000208	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—AKT1—malignant glioma	1.51e-05	0.000207	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—STAT3—malignant glioma	1.51e-05	0.000206	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PTGS1—malignant glioma	1.51e-05	0.000206	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—PIK3CA—malignant glioma	1.5e-05	0.000205	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MDM2—malignant glioma	1.5e-05	0.000205	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CD80—malignant glioma	1.5e-05	0.000205	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—APC—malignant glioma	1.49e-05	0.000204	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CG—malignant glioma	1.49e-05	0.000204	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—VEGFA—malignant glioma	1.49e-05	0.000204	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—RAF1—malignant glioma	1.49e-05	0.000204	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—STAT3—malignant glioma	1.48e-05	0.000202	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—EGF—malignant glioma	1.48e-05	0.000202	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—ERBB2—malignant glioma	1.47e-05	0.000202	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PTPN11—malignant glioma	1.47e-05	0.000201	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CB—malignant glioma	1.46e-05	0.000199	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MYC—malignant glioma	1.41e-05	0.000193	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—BRAF—malignant glioma	1.4e-05	0.000192	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MYC—malignant glioma	1.4e-05	0.000192	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—BCHE—malignant glioma	1.4e-05	0.000192	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—VEGFA—malignant glioma	1.4e-05	0.000192	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CXCL8—malignant glioma	1.4e-05	0.000191	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—STAT3—malignant glioma	1.39e-05	0.00019	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SLC5A5—malignant glioma	1.38e-05	0.000189	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—EGFR—malignant glioma	1.38e-05	0.000189	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MYC—malignant glioma	1.37e-05	0.000188	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—EGFR—malignant glioma	1.37e-05	0.000188	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CB—malignant glioma	1.37e-05	0.000187	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AKT2—malignant glioma	1.37e-05	0.000187	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—EGFR—malignant glioma	1.36e-05	0.000186	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PTGS2—malignant glioma	1.36e-05	0.000185	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CAV1—malignant glioma	1.36e-05	0.000185	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—AKT1—malignant glioma	1.35e-05	0.000185	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—EGFR—malignant glioma	1.34e-05	0.000184	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CASP3—malignant glioma	1.34e-05	0.000183	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL2—malignant glioma	1.34e-05	0.000183	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CD—malignant glioma	1.31e-05	0.00018	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—KRAS—malignant glioma	1.3e-05	0.000178	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—PIK3CA—malignant glioma	1.3e-05	0.000178	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—KRAS—malignant glioma	1.29e-05	0.000177	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MYC—malignant glioma	1.29e-05	0.000176	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—KRAS—malignant glioma	1.28e-05	0.000176	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—KRAS—malignant glioma	1.27e-05	0.000173	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MMP9—malignant glioma	1.26e-05	0.000173	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—EGFR—malignant glioma	1.26e-05	0.000172	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PTEN—malignant glioma	1.26e-05	0.000172	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—FGF2—malignant glioma	1.26e-05	0.000172	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CG—malignant glioma	1.23e-05	0.000169	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—AKT1—malignant glioma	1.23e-05	0.000168	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PIK3CA—malignant glioma	1.2e-05	0.000164	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PPARG—malignant glioma	1.19e-05	0.000163	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—KRAS—malignant glioma	1.19e-05	0.000163	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PIK3CA—malignant glioma	1.19e-05	0.000163	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PTEN—malignant glioma	1.18e-05	0.000162	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—PIK3CA—malignant glioma	1.18e-05	0.000161	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MDM2—malignant glioma	1.18e-05	0.000161	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—RAF1—malignant glioma	1.17e-05	0.00016	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PIK3CA—malignant glioma	1.16e-05	0.000159	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TP53—malignant glioma	1.16e-05	0.000159	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ERBB2—malignant glioma	1.16e-05	0.000159	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TP53—malignant glioma	1.15e-05	0.000157	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CB—malignant glioma	1.14e-05	0.000156	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—VEGFA—malignant glioma	1.14e-05	0.000155	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TP53—malignant glioma	1.13e-05	0.000154	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—STAT3—malignant glioma	1.12e-05	0.000154	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTP1—malignant glioma	1.11e-05	0.000153	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CXCL8—malignant glioma	1.1e-05	0.00015	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PIK3CA—malignant glioma	1.09e-05	0.00015	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CD—malignant glioma	1.09e-05	0.000148	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CAT—malignant glioma	1.08e-05	0.000148	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—AKT1—malignant glioma	1.06e-05	0.000145	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TP53—malignant glioma	1.06e-05	0.000145	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CASP3—malignant glioma	1.05e-05	0.000144	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL2—malignant glioma	1.05e-05	0.000144	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MYC—malignant glioma	1.05e-05	0.000143	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NCOR1—malignant glioma	1.02e-05	0.00014	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—EGFR—malignant glioma	1.02e-05	0.00014	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MMP9—malignant glioma	9.94e-06	0.000136	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PTEN—malignant glioma	9.88e-06	0.000135	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—AKT1—malignant glioma	9.79e-06	0.000134	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—AKT1—malignant glioma	9.72e-06	0.000133	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—KRAS—malignant glioma	9.66e-06	0.000132	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—AKT1—malignant glioma	9.64e-06	0.000132	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—AKT1—malignant glioma	9.51e-06	0.00013	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CB—malignant glioma	9.46e-06	0.000129	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PTGS2—malignant glioma	9.37e-06	0.000128	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—AKT1—malignant glioma	8.94e-06	0.000122	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—VEGFA—malignant glioma	8.93e-06	0.000122	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CA—malignant glioma	8.87e-06	0.000121	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—STAT3—malignant glioma	8.84e-06	0.000121	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TP53—malignant glioma	8.58e-06	0.000117	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CAV1—malignant glioma	8.35e-06	0.000114	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CA—malignant glioma	8.34e-06	0.000114	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MYC—malignant glioma	8.21e-06	0.000112	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PTEN—malignant glioma	8.17e-06	0.000112	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—EGFR—malignant glioma	8.03e-06	0.00011	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CG—malignant glioma	7.61e-06	0.000104	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—KRAS—malignant glioma	7.59e-06	0.000104	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PPARG—malignant glioma	7.34e-06	0.0001	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—AKT1—malignant glioma	7.25e-06	9.92e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CA—malignant glioma	6.97e-06	9.54e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—AKT1—malignant glioma	6.81e-06	9.32e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TP53—malignant glioma	6.75e-06	9.23e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CD—malignant glioma	6.69e-06	9.15e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CB—malignant glioma	5.83e-06	7.97e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PTGS2—malignant glioma	5.77e-06	7.9e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CA—malignant glioma	5.77e-06	7.89e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AKT1—malignant glioma	5.7e-06	7.79e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PTEN—malignant glioma	5.04e-06	6.89e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—AKT1—malignant glioma	4.71e-06	6.45e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CA—malignant glioma	3.55e-06	4.86e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—AKT1—malignant glioma	2.9e-06	3.97e-05	CbGpPWpGaD
